Obama Stroking Pro-Abort Dem Base in Approving Embryonic Stem Cell Test in Humans?

July 30, 2010 - San Francisco, CA - PipeLineNews.org - If one is to judge by actions, the decision by the FDA to allow Geron [a bio-pharma research company] to commence human testing of one of its treatments designed to be of use in healing spinal cord injuries, could be a crassly political move to shore up his support among his dispirited base as November 2 approaches.

According to critics, Geron's process hasn't even been proven in rat, let alone in tests on higher animals, "It's unfortunate that the FDA has released Geron from the safety hold on their embryonic stem cell trial," he said. "Even many pro-embryonic stem cell scientists have expressed reservations about Geron's trial, that it is not proven even in rats. The concern for many of us is that Geron is endangering patient's health and very lives, to make a political point and increase their stock price." [source, http://lifenews.com/bio3137.html]

Geron makes no profits as the Motley Fool notes, though it does have a considerable potential upside. This lack of product generated income is, along with a high cash burn rate, the reason why these stock tipsters suggested dumping it at the beginning of this year. [source, 3 Reasons to Sell Geron Today, http://www.fool.com/investing/general/2010/01/25/3-reasons-to-sell-geron-today.aspx]

Geron's stock price had been dropping since that warning...until the FDA made the announcement that the NRNOPC1 test would go forward. [source, http://www.google.com/finance?client=ob&q=NASDAQ:GERN]

Geron's president/CEO has made at least one key political donation, to RINO Congressman Michael Castle, whose seat has been targeted by conservatives because of his liberal voting record.

Thomas B. Okarma, Ph.D., M.D, President, Chief Executive Officer andDirector, has according to the FEC, contributed to the campaign of Michael Castle [R, DE] self described as, "the House architect of the Congressional effort to expand federal stem cell research policy. He authored The Stem Cell Research Enhancement Act, which has been vetoed twice by President Bush. [source, http://www.castle.house.gov/Issues/Issue/?IssueID=4449]

Okarma admits to having "engineered," the timing of its request for trial so as not to fall under the jurisdiction of the George W. Bush administration.

"Many people hypothesised the first time that the lifting of the hold was due to the Administration change. We have no information and no indication that that was the case. We engineered the timing, because our final submission was timed such that the 30-day window occurred after the inauguration of President Obama. That was our design, not really an Administration change. That was our timing. We did not want this to come up under the Bush Administration. We designed it." [source, Geron engineered stem cell application so Obama could announce approval, UK Times Online, http://timesonline.typepad.com/science/2010/02/geron-engineered-stem-cell-application-so-obama-could-approve-it.html]

Okarma has also urged Obama to, "appoint a commission on stem cell research to help the therapy fulfill its promise to save lives and reduce medical costs, Geron Corp. Chief Executive Officer Tom Okarma said...Okarma proposed the national commission as part of a group from the Biotechnology Industry Organization, a Washington-based industry trade association, he said yesterday in an interview. Okarma is a member of the health section of the association's board of directors.

Okarma has also made political contributions to the Biotechnology Industry Organization PAC, which in turn helps fund industry friendly legislators.

While none of this is improper, it does raise questions regarding this administration's apparent penchant for selecting winners and losers in today's high-stakes economy. It also demonstrates the need, at this critical point in his presidency, for Obama to send further accommodational signals to his hard left base.

© 2010. All rights reserved. .